SCHEMBL6516182

SCHEMBL6516182

COc1ccc(S(=O)(=O)c2c[nH]c3ccc(Oc4c(C)cc(C[C@@H](N)C(=O)O)cc4C)cc23)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.55
THRB P10828 8/20 0.48
THRA P10827 7/20 0.48
TP53 P04637 1/20 0.46
LMNA P02545 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
HTT P42858 1/20 0.45
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
HSP90AA1 P07900 1/20 0.43
HSP90AB1 P08238 1/20 0.43
LTA4H P09960 1/20 0.43
PLA2G2A P14555 1/20 0.43
KDM4E B2RXH2 1/20 0.41
MMP2 P08253 3/20 0.41
MMP9 P14780 2/20 0.41
RXFP1 Q9HBX9 1/20 0.40
CYP2D6 P10635 1/20 0.40
TSHR P16473 1/20 0.40
GABRP O00591 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6513062 1.00 MAPT (0.55) MAPTTHRBTHRATP53LMNA
SCHEMBL6514304 0.94 MAPT (0.56) MAPTTHRBTHRATP53LMNA
SCHEMBL6514297 0.94 MAPT (0.56) MAPTTHRBTHRATP53LMNA
SCHEMBL6515951 0.93 THRB (0.50) MAPTTHRBTHRALMNASMN1; SMN2
SCHEMBL6511198 0.93 THRB (0.50) MAPTTHRBTHRALMNASMN1; SMN2
SCHEMBL6523587 0.92 SMN1; SMN2 (0.48) MAPTTHRBTHRATP53LMNA
SCHEMBL6513027 0.92 SMN1; SMN2 (0.48) MAPTTHRBTHRATP53LMNA
SCHEMBL6512601 0.92 SMN1; SMN2 (0.48) MAPTTHRBTHRATP53LMNA
SCHEMBL6521706 0.92 SMN1; SMN2 (0.48) MAPTTHRBTHRATP53LMNA
SCHEMBL6515174 0.91 MAPT (0.51) MAPTTHRBTHRATP53LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032874-A1 Anticholesterol agents; arteriosclerosis BAYER AKTIENGESELLSCHAFT (DE) 2005-02-10 US disclosed
US-6794406-B2 FOR THERAPY AND PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA BAYER AKTIENGESELLSCHAFT (DE) 2004-09-21 US disclosed
EP-1347959-A1 INDOLE DERIVATIVES AS LIGANDS OF THYROID RECEPTORS Bayer Aktiengesellschaft (DE) 2003-10-01 EP disclosed
US-20030078288-A1 Indole derivatives BAYER AKTIENGESELLSCHAFT (DE) 2003-04-24 US disclosed
WO-2002051805-A1 INDOLE DERIVATIVES AS LIGANDS OF THYROID RECEPTORS BAYER AKTIENGESELLSCHAFT (DE) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078288-A1 Indole derivatives IDO1, IDO2, TPH2 MAPT 839/4885THRB 1772/4885THRA 2460/4885
US-20050032874-A1 Anticholesterol agents; arteriosclerosis HMGCR, CYP46A1, EBP MAPT 3453/4885THRB 1835/4885THRA 1917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.